Numira Appoints Dr. Gonzalo Castillo As Scientific Director Of Oncology

SALT LAKE CITY, Feb. 25, 2014 /PRNewswire/ -- Numira, a leader in high resolution, 3D imaging services, visualization software, and cloud computing for the life science market, today announced the appointment of Gonzalo Castillo, Ph.D. as Scientific Director of Oncology.

"I'm pleased to welcome Dr. Castillo to the Numira scientific team," said Hal Widlansky, CEO of Numira. "In this next phase of Numira's evolution, Gonzalo's excellent reputation in the field of oncology, recognized leadership in molecular pharmacology and commitment to excellence will be invaluable in advancing our technology and assisting our clients in their discovery efforts."

Dr. Castillo brings over 15 years of industry experience and will oversee Numira's Oncology division, developing and supporting Numira's Oncology services including 3D cell screening assay. 3D cell screening has been shown to more effectively predict in vivo compound efficacy.

Prior to joining Numira, Gonzalo was the in vitro Technical Director at Eurofins Panlabs, responsible for the scientific strategy of their in vitro pharmacology portfolio and served as technical support for the sales and marketing team. He holds an undergraduate degree in Biochemistry from Universidad de Concepcion, Chile and a Doctorate degree in Molecular Pharmacology from the Albert Einstein College of Medicine. His postdoctoral work was carried out at the Dana Farber Cancer Institute, Harvard Medical School.

"I am very excited about joining the talented scientific team at Numira," exclaims Castillo. "There is enormous potential to accelerate cancer drug development by utilizing Numira's proprietary technologies like AltaBlu Prime Tumor vascularization imaging and 3D compound efficacy screening. I look forward to working closely with the drug developing community to engage our cutting edge technologies to improve the chances of clinical success."

About Numira

Numira is a specialized preclinical contract research organization (CRO) assisting pharmaceutical, biotech, and medical device companies to understand the efficacy of their products at the early stages of development. Utilizing patented imaging protocols and 3D quantitative analysis tools, Numira delivers images, metrics, and analyses that provide definitive results rapidly and accurately. Focused on therapeutic areas such as CNS, bone, pulmonary, oncology, and inflammation, Numira's novel customized solutions provide researchers with new insights and greater accuracy in a cost-effective and timely manner, helping to expedite the discovery process. For more information visit www.numira.com.

SOURCE Numira